$20.31-1.08 (-5.05%)
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
Regencell Bioscience Holdings Limited in the Healthcare sector is trading at $20.31. The stock is currently near its 52-week low of $9.39, remaining 9.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerati...
Regencell Bioscience Holdings (NasdaqCM:RGC) has changed its independent auditor. The company disclosed the auditor replacement as a material corporate governance event. The change could affect how Regencell approaches financial reporting and internal controls going forward. Regencell Bioscience Holdings operates in the bioscience space, where investor attention often centers on research pipelines, regulatory milestones and funding capacity. In this context, an auditor change is not just an...
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 87 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg
Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.
Regencell Bioscience Holdings (NasdaqCM:RGC) is under investigation by the U.S. Department of Justice over trading in its ordinary shares and various corporate, financial, and accounting matters, placing legal risk firmly in focus for investors. See our latest analysis for Regencell Bioscience Holdings. The stock has been volatile, with a 1 day share price return of a 4.87% decline and a 7 day decline of 7.91%, yet a 90 day share price return of 49.08%. The 1 year total shareholder return is...
Regencell Bioscience is working on TCM opportunities, but what exactly is TCM?